Wave Life Sciences Ltd. (WVE) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Wave Life Sciences Ltd.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biotechnology company focused on RNA medicines (oligonucleotides) using its proprietary PRISM platform. The company utilizes modalities including RNAi (SpiNA) and RNA editing (AIMers) to treat rare and common disorders.
Key Pipeline Programs:
- Obesity (WVE-007): GalNAc-siRNA targeting INHBE. Phase 1 data showed fat loss with muscle preservation.
- Alpha-1 Antitrypsin Deficiency (WVE-006): RNA editing oligonucleotide. Company regained full rights from GSK in February 2026.
- PNPLA3 I148M Liver Disease (WVE-008): RNA editing oligonucleotide.
- Duchenne Muscular Dystrophy (WVE-N531): Exon 53 splicing oligonucleotide.
- Huntington's Disease (WVE-003): Allele-selective oligonucleotide.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $42.7 million | $108.3 million | (60.6%) |
| Net Loss | $(204.4) million | $(97.0) million | Widened |
| Operating Expenses | $258.1 million | $218.7 million | +18.0% |
| R&D Expenses | $182.8 million | $159.7 million | +14.5% |
| G&A Expenses | $75.3 million | $59.0 million | +27.6% |
| Cash & Equivalents (End of Period) | $602.1 million | $302.1 million | +99.3% |
| Accumulated Deficit | $(1,326.2) million | $(1,121.9) million | N/A |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product revenue and is in a pre-commercial stage.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $65.6 million primarily due to the termination of the Takeda Collaboration Agreement in October 2024, which had contributed $71.3 million in 2024 revenue. This was partially offset by increased revenue from the GSK Collaboration Agreement.
- Increased Operating Loss: Net loss more than doubled to $204.4 million, driven by higher operating expenses ($258.1 million vs. $218.7 million) and lower revenue.
- R&D Spend Shifts: R&D expenses increased by $23.1 million. Notable increases occurred in the INHBE (Obesity) program (+$6.4M) and DMD program (+$3.9M), while spending on the HD program decreased significantly (-$9.1M) following the Takeda termination.
- Liquidity Improvement: Cash and cash equivalents nearly doubled to $602.1 million, bolstered by a December 2025 underwritten public offering that raised approximately $402.5 million in gross proceeds and $94.6 million from "at-the-market" sales.
Guidance, Outlook, and Risks
Outlook and Milestones:
- WVE-007 (Obesity): Phase 1 data (INLIGHT study) showed a 9.4% reduction in visceral fat and 3.2% increase in lean mass at 3 months. Phase 2a initiation planned for H1 2026.
- WVE-006 (AATD): Company regained full rights from GSK. Regulatory engagement accelerated; feedback on accelerated approval pathway expected mid-2026.
- WVE-N531 (DMD): Plans to file a New Drug Application (NDA) in 2026 for accelerated approval.
- WVE-003 (HD): FDA granted Orphan Drug Designation in November 2024; IND for Phase 2/3 study planned for submission with a strategic partner.
Capital Requirements: Management expects existing cash resources to fund operations for at least the next 12 months. The company anticipates continuing to incur significant operating losses for the foreseeable future.
Key Risks:
- Profitability: History of losses with no product revenue; may never achieve profitability.
- Regulatory Approval: Clinical-stage company with no approved products; clinical trials may fail or be delayed.
- Collaboration Dependence: Revenue relies heavily on collaboration agreements (e.g., GSK); termination of such agreements impacts revenue significantly.
- Manufacturing: Reliance on third-party manufacturers and internal cGMP capabilities; supply chain disruptions could delay trials.
- Intellectual Property: Risks related to patent enforcement and third-party challenges.
Investor Verification Checklist
- Cash Runway: Verify the $602.1 million cash balance against the projected burn rate to confirm the 12-month liquidity assertion.
- WVE-007 Clinical Data: Review the full Phase 1 INLIGHT study data regarding visceral fat reduction and muscle preservation to assess commercial potential against GLP-1 competitors.
- GSK Collaboration Status: Confirm the terms of the ongoing GSK collaboration and the specific impact of regaining full rights to WVE-006 on future revenue recognition.
- R&D Allocation: Analyze the shift in R&D spending toward the Obesity and DMD programs versus the reduction in HD spending.
- Regulatory Pathways: Monitor FDA feedback on the accelerated approval pathways for WVE-006 (AATD) and WVE-N531 (DMD) expected in 2026.